This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical.
MoonLake Immunotherapeutics appoints Jorge Santos da Silva as CEO and Matthias Bodenstedt as CFO finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody®,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F
05/03/2021 | 08:01am EDT
Send by mail :
Message :
Required fields
ZUG, Switzerland, May 3, 2021 /PRNewswire/ MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced that it has in-licensed the Tri-specific Nanobody
® Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany.
MoonLake Immunotherapeutics has been established by an international team of immunology specialists to leverage revolutionary Nanobody
® (single-domain antibody) technology in multiple indications. It will accelerate the clinical development of Sonelokimab, building on robust clinical data generated by Merck KGaA, Darmstadt, Germany, and by